NCT04428203View on ClinicalTrials.gov

Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

August 20, 2021

Study Completion Date

August 20, 2021

Conditions
Prostate Cancer RecurrentProstate CancerProstate Adenocarcinoma
Interventions
DRUG

Epidiolex Oral Liquid Product

600 mg Oral solution

DRUG

Epidiolex Oral Liquid Product

800 mg oral solution

DRUG

Epidiolex Oral Liquid Product

800 mg oral solution

Trial Locations (1)

40536

Markey Cancer Center, Lexington

All Listed Sponsors
lead

Zin W Myint

OTHER

NCT04428203 - Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter